Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2022-02-10 08:00:00
Oslo, 10 February 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical
stage leader in immune stimulatory vaccines for cancer, invites to a webcast
presentation of its fourth quarter 2021 results on Thursday 17 February 2022.
The presentation can be followed as a live webcast accessed through a link on
www.ultimovacs.com (http://www.ultimovacs.com) at 09:00 CET on Thursday 17
February 2022. The webcast presentation will be available on the Ultimovacs
website, and it will be possible to post questions during the presentation
through the webcast.
The report and presentation will be available on the company website from 08:00
CET the same day.
For further information, please see www.ultimovacs.com
(http://www.ultimovacs.com) or contact:
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com (mailto:carlos.desousa@ultimovacs.com)
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com (mailto:hans.eid@ultimovacs.com)
Phone: +47 482 48632
Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com (mailto:anne.worsoe@ultimovacs.com)
Phone: +47 906 86815
Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com (mailto:mchang@lifesciadvisors.com)
Phone: +44 7483 284 853